Article original2026
Patrick Kabongo Mutombo, Gédéon Kalala Tshimanga, Hypolite Muhindo Mavoko, Kabongo Mutombo P, Kalala Tshimanga G, Hypo Mavoko JP
Whole-genome sequencing of 248 Mpox virus isolates from 14 provinces in DRC reveals substantial genetic diversity and identifies novel clades with potential implications for vaccine efficacy.
Communication courte2026
Aimée Kahindo Kiyonga, Patrick Kabongo Mutombo, Francis Kasongo Mumba, Ngoie Banza A, Kabongo Mutombo P, Kasongo Mumba F
Description of the design and first-year results of the ARBO-SENTINEL network, a multi-country sentinel surveillance system for dengue, chikungunya, yellow fever and Zika viruses in Central Africa.
Méta-analyse2026
Gédéon Kalala Tshimanga, Sterling Ilunga Kabongo, Béatrice Mwamba Kalala, Kalala Tshimanga G, Ilunga Kabongo S, Mwamba Kalala B
A systematic review and meta-analysis of 87 studies reporting molecular markers of antimalarial drug resistance in P. falciparum from Central Africa, revealing emerging artemisinin partial resistance in western DRC.
Cas clinique2026
Gracia Tshibangu Lukusa, Marie-Claire Mukendi Ngoy, Espoir Bokamba Okito, Tshibangu Lukusa G, Mukendi Ngoy MC, Bokamba Okito E
Case report describing a severe Mpox infection with multi-organ involvement in an HIV-positive patient in Kinshasa, highlighting the need for enhanced clinical management protocols in endemic areas.
Article original2026
Hypolite Muhindo Mavoko, Patrick Kabongo Mutombo, Marie-Claire Mukendi Ngoy, Hypo Mavoko JP, Kabongo Mutombo P, Mukendi Ngoy MC
A randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen among healthcare workers and at-risk populations in the Democratic Republic of the Congo.
Article original2026
Sterling Ilunga Kabongo, Gédéon Kalala Tshimanga, Ilunga Kabongo S, Kalala Tshimanga G
Étude transversale évaluant la prévalence de la résistance aux pyréthrinoïdes chez Anopheles gambiae s.l. dans quatre zones de santé de Kinshasa à l'aide de tests OMS et de caractérisation moléculaire.
Article original2026
Marie-Claire Mukendi Ngoy, Gracia Tshibangu Lukusa, Mukendi Ngoy MC, Tshibangu Lukusa G
This multicentre randomised phase III trial demonstrates non-inferiority of oral fexinidazole compared to the standard NECT regimen for stage 2 HAT, with a cure rate of 95.2% vs 93.8% at 18 months.